title: Recent clinical experience with oncolytic viruses.
abstract: There has been interest in using viruses to treat cancer for over a century. Recent clinical efforts, driven on by significant preclinical advances, have focussed on the safety of using replication-competent viruses. Recently published clinical trials of six oncolytic viruses (adenovirus, reovirus, measles, herpes simplex, Newcastle disease virus and vaccinia) have added to the accumulating data that endorse oncolytic viruses as a safe and well tolerated treatment approach. Conclusive evidence of efficacy remains to be demonstrated, but randomised clinical trials are now underway.
authors: Leeds Institute of Molecular Medicine, St James's University Hospital, Beckett Street, Leeds, UK.
authors: O G
authors: OG
authors: Donnelly
authors: F
authors: F
authors: Errington-Mais
authors: R
authors: R
authors: Prestwich
authors: K
authors: K
authors: Harrington
authors: H
authors: H
authors: Pandha
authors: R
authors: R
authors: Vile
authors: A A
authors: AA
authors: Melcher
mesh_terms: D002986:Clinical Trials as Topic; D004353:Drug Evaluation, Preclinical; D006801:Humans; D009369:Neoplasms / Q000628:therapy* / Q000821:virology*; D050130:Oncolytic Virotherapy / Q000379:methods*; D050504:Oncolytic Viruses / Q000502:physiology*; D014779:Virus Replication